LipimetiX is focused on the cost-efficient development of its technology through a virtual company structure under the leadership of experienced scientists and biotech business executives, through a partnership between Benu BioPharma and Capstone Therapeutics. >> Read More
The Apo E mimetics were developed through the intimate knowledge of the structure and function of the receptor and lipid binding domains of the apolipoproteins.
>> Read More
Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
>> Read More
LipimetiX Development was established as a joint venture between Capstone Therapeutics Corp. (OTCQB: CAPS), and LipimetiX, Inc.
We are a privately held biopharmaceutical company created to develop a novel class of drugs to treat refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by rapidly decreasing arterial cholesterol content and inflammation. LipimetiX's technology is based upon a platform of chimeric peptide mimetics of apolipoprotein E, a critical protein that directs cholesterol and triglyceride rich lipoproteins to receptors on the liver. LipimetiX's base peptide, AEM-28, has demonstrated remarkable VLDL cholesterol and triglyceride reductions in Phase 1 and Phase 2 human clinical trials. More potent analogs of AEM-28 are currently being developed for acute pancreatitis, refractory hypertriglyceridemia and genetically induced refractory hypercholesterolemia, orphan indications that lead to early cardiovascular disease. AEM-28 has been granted orphan drug designation from the FDA.